Capital Resource Partners provides Capital for Growth at Medmark Services
December 30, 2008

VaxInnate announces 'universal' flu vaccine passed early test
November 11, 2008

Resolvyx Announces Open IND for RX-10045, the Lead Resolvin Therapeutic for Dry Eye
November 20, 2008

National Neurovision Research Institute (NNRI) and Resolvyx Pharmaceuticals Collaborate to Assess Resolvins to Treat Degenerative Eye Diseases
November 20, 2008

Vertos Medical, Inc. Appoints James M. Corbett Chief Executive Officer
November 7, 2008

Millennium Pharmacy Systems Expands into West Virginia
November 5, 2008

3M and VaxInnate Collaborate to Develop Flu Vaccine Patch
October 22, 2008

VaxInnate To Present Positive Results from Clinical Trial of Universal Flu Vaccine Candidate at ICAAC/IDSA Meeting
October 14, 2008

VaxInnate's Second Flu Vaccine Candidate Enters Clinical Deployment; Results Expected in Early 2009
September 30, 2008

Millennium Pharmacy Systems among 500 Fastest Growing US Companies
September 23, 2008

Millennium Pharmacy Systems, Inc. Appoints New CEO
September 10, 2008

VaxInnate's M2e Universal Influenza Vaccine Candidate Demonstrates Safety and Immunogenicity in Phase I Clinical Study
August 14, 2008

AscendHealth Announces Acquisition in Portland, Oregon
August 11, 2008

Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting with FDA for Amigal in Fabry Disease
August 4, 2008

Vertos Medical Inc. Completes Series C Financing
July 17, 2008

Vertos Medical Inc. Presents Clinical Data of its MILD™ Procedure at the 5th Annual Innovative Techniques in Spine Surgery Conference in Los Cabos, Mexico
July 17, 2008

Resolvyx Scientific Advisors Publish First In-Vivo Data Showing Resolvins Suppress IL-23 and IL-17, Key Mediators of Inflammatory Disease
July 3, 2008

MedMark Treatment Centers Opens Fresno Facility
June 30, 2008

FierceBiotech Names Resolvyx Pharmaceuticals as One of the "Fierce 15" Biotech Companies of 2008
June 24, 2008

BioRelix Rounds Up $26 Million First Round
June 8, 2008

Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
June 3, 2008

MedMark Services Relocates Corporate Headquarters to Texas
May 15, 2008

Emerging Drug Developer: Resolvyx Pharmaceuticals
May 12, 2008

Resolvyx Compounds Show Promise In Treatment of Ocular Disease
May 1, 2008

Bedford biotech gains steam and attention
April 22, 2008

Resolvyx Pharmaceuticals Strengthens Its Board of Directors with Industry Leaders
April 22, 2008

Resolvyx Pharmaceuticals Raises $25 Million in Series B Financing
April 22, 2008

Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
March 13, 2008

Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
March 13, 2008

Medicus Insurance Holdings, Inc. Secures Additional Funding from The Cypress Group and CHL Medical Partners
March 11, 2008

BIKAM and Dalton Medicinal Chemistry Sign Collaborative Research Agreement
March 3, 2008

OpGen, Inc. Appoints Noel Doheny as Chief Executive Officer
January 30, 2008

Amicus Therapeutics Announces Positive Interim Results From Phase 2 Clinical Trial of Plicera™ for Gaucher Disease
January 7, 2008

Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
December 19, 2007

Resolvyx Pharmaceuticals:  Fish Oil Mystery Solved, Blockbuster Drugs to Follow
November 30, 2007

AscendHealth announces the opening of University Behavioral Health of El Paso.
November 30, 2007

Amicus Therapeutics and Shire plc Enter Into $440 Million ex-US Licensing Agreement to Develop and Commercialize Amigal(TM), Plicera(TM) and At2220
November 8, 2007

OpGen Announces Strategic Investment and Technology Advancement Agreement with In-Q-Tel
October 29, 2007

VaxInnate Initiates Phase I Clinical Study of M2e Universal Influenza Vaccine
September 25, 2007

OpGen Announces $23.6 Million Series A Financing
September 12, 2007

VaxInnate Awarded NIH Funding for Collaborative Dengue Fever Vaccine Development
July 23, 2007

Millennium Pharmacy Systems Completes $40 Million Financing
June 12, 2007

Amicus Therapeutics Announces Pricing of Initial Public Offering of 5,000,000 Shares of Common Stock
May 31, 2007

Spine Wave Receives FDA Clearance for CapSure™ PS Pedicle Screw System; U.S. Sales Force Expansion Underway to Support Product Portfolio
April 17, 2007

Spine Wave Receives FDA Clearance for the StaXx® FX Structural Kyphoplasty System
April 16, 2007

Spine Wave Closes $45 Million Financing; Device Company to Expand Sales Force, Product Development and Clinical Trials
April 10, 2007

Ascend Health Raises $20.1 million Series B Financing
March 26, 2007

Amicus Therapeutics Presents Positive Results from Phase 1 Clinical Studies of Plicera™ for Gaucher Disease; Phase 2 Clinical Trials Initiated
March 21, 2007

Amicus Therapeutics Completes Phase 2 Enrollment or Amigal™ for Fabry Disease
March 16, 2007